We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...